Evaluating Medication Adherence of Patients With Gastroesophageal Reflux Disease With Support of the Smartphone Application GERDCare
AppGERD
1 other identifier
interventional
380
1 country
1
Brief Summary
Adherence to GERD treatment, including medication, diet, and lifestyle, is essential for symptom control and complication prevention, yet adherence rates remain low due to various demographic and clinical factors. Digital therapeutics, particularly mobile health applications, have shown promising potential in supporting chronic disease management and improving patient outcomes. The GERDCare mobile application was developed with direct input from gastrointestinal experts. It is designed to enhance treatment adherence and patient engagement by offering features such as educational resources, symptom tracking, medication reminders, and direct communication between patients and physicians. The investigators are conducting a single-center, open-label, randomized controlled trial to evaluate the effectiveness of using GERDCare in improving patient adherence. Patients are followed up after four weeks of GERD treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Aug 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 8, 2025
CompletedFirst Posted
Study publicly available on registry
August 15, 2025
CompletedStudy Start
First participant enrolled
August 18, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2026
ExpectedMarch 25, 2026
March 1, 2026
9 months
August 8, 2025
March 24, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion of patients with good adherence at 4 weeks
Patients achieved a score of ≥27 points on the Vietnamese Version of the General Medication Adherence Scale (GMAS). Higher scores mean better adherence.
4 weeks after recruitment
Secondary Outcomes (3)
Changes in GERD symptom severity
4 weeks after recruitment
Proportion of patients with clinical improvement after 4 weeks
4 weeks after recruitment
Changes of patients' quality of life after 4 weeks
4 weeks after recruitment
Study Arms (2)
Using GERDCare
EXPERIMENTALUsing the mobile phone application GERDCare (with detailed instructions provided during recruitment)
Not using GERDCare
NO INTERVENTIONNot using the smartphone application GERDCare
Interventions
Using the smartphone application GERDCare (with detailed instructions provided during recruitment)
Eligibility Criteria
You may qualify if:
- ≥18 years old
- Presents with typical GERD symptoms (regurgitation, heartburn)
- Owns a smartphone and capable of using smartphone applications.
You may not qualify if:
- Acute GI conditions (upper GI bleeding, acute peptic ulcer…)
- GI malignancy (esophageal cancer, gastric cancer…)
- Severe chronic comorbidities (heart failure, liver failure, chronic kidney disease…)
- Pregnancy, alcohol abuse, mental health conditions impacting medication adherence or app usage
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Institute of Gastroenterology and Hepatology
Hanoi, 100000, Vietnam
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 8, 2025
First Posted
August 15, 2025
Study Start
August 18, 2025
Primary Completion
April 30, 2026
Study Completion (Estimated)
May 31, 2026
Last Updated
March 25, 2026
Record last verified: 2026-03